Page 1 | Search Results | Blood | American Society of Hematology

1-20 of 30

Sort by

Sort Order Select

Journal Articles

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Benjamin F. Frost, Noelle Frey, Elizabeth O. Hexner, Stephen J. Schuster, Sunita D. Nasta, Alison W Loren, Jakub Svoboda, Daniel J. Landsburg, Bruce Levine, Joseph A. Fraietta, J. Joseph Melenhorst, Elizabeth Veloso, Wei-Ting Hwang, Carl H. June, David L. Porter, Saar Gill

Blood (2024) 144 (Supplement 1): 588.

https://doi.org/10.1182/blood-2024-204197

Published: 2024

Journal Articles

Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Julia Han Noll, Humza Hemani, Jiang Yuan Li, Kevin R. Amses, Bruce Levine, Carl H. June, Nan-Ping Weng, Joseph A. Fraietta

Blood (2024) 144 (Supplement 1): 2051.

https://doi.org/10.1182/blood-2024-200721

Published: 2024

Journal Articles

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

Blood (2024) 144 (Supplement 1): 7243.

https://doi.org/10.1182/blood-2024-206608

Published: 2024

Journal Articles

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Blood (2024) 144 (Supplement 1): 3473.

https://doi.org/10.1182/blood-2024-210324

Published: 2024

Journal Articles

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Allison Barz Leahy, Jennifer Brogdon, Lucy Cain, Amanda M. Dinofia, Joseph A. Fraietta, Richard Hanna, Stephan Kadauke, Raabia Khan, Yimei Li, Shannon L. Maude, Regina M. Myers, Laura Shinehouse, Anna Sparrow, Melissa Varghese, Lei Wang, Yongping Wang, Stephan A. Grupp

Blood (2024) 144 (Supplement 1): 3470.

https://doi.org/10.1182/blood-2024-204300

Published: 2024

Journal Articles

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

Blood (2024) 144 (Supplement 1): 499.

https://doi.org/10.1182/blood-2024-198249

Published: 2024

Journal Articles

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Blood (2024) 144 (Supplement 1): 909.

https://doi.org/10.1182/blood-2024-202659

Published: 2024

Journal Articles

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

Blood (2023) 142 (Supplement 1): 4483.

https://doi.org/10.1182/blood-2023-182234

Published: 2023

Journal Articles

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Caroline Diorio, Regina M. Myers, Anastasia Frank-Kamenetski, Rawan Shraim, Amanda M. Dinofia, Zachary Martinez, Ohaila Mustafa, Joseph A Fraietta, Vanessa Gonzalez, Vivian Yi, Lahari Uppuluri, Haley Newman, Edward Behrens, Carl June, Scott Canna, Stephan Grupp, David T. Teachey

Blood (2023) 142 (Supplement 1): 3431.

https://doi.org/10.1182/blood-2023-182377

Published: 2023

Journal Articles

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

Blood (2023) 142 (Supplement 1): 217.

https://doi.org/10.1182/blood-2023-182104

Published: 2023

Journal Articles

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Blood (2022) 140 (Supplement 1): 2376–2377.

https://doi.org/10.1182/blood-2022-168139

Published: 2022

Journal Articles

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Blood (2021) 138 (Supplement 1): 166.

https://doi.org/10.1182/blood-2021-152664

Published: 2021

Journal Articles

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Natalie F. Uy, MD, Edward Pequignot, Noelle V. Frey, MD, Megan Davis, PhD, Elizabeth O. Hexner, MD, Stephen J. Schuster, MD, Saar Gill, MD PhD, Alison W. Loren, MD, Stephan A Grupp, MD PhD, J. Joseph Melenhorst, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Joan Gilmore, BS, Lester Lledo, RN,NP, Wei-Ting Hwang, PhD, Don L. Siegel, MD PhD, Bruce L Levine, PhD, Carl H June, MD, David L. Porter, MD

Blood (2020) 136 (Supplement 1): 30–32.

https://doi.org/10.1182/blood-2020-141224

Published: 2020

Journal Articles

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Blood (2019) 134 (Supplement_1): 622.

https://doi.org/10.1182/blood-2019-122513

Published: 2019

Journal Articles

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

Meng Wang, BS, Iulian Pruteanu, PhD, Adam D. Cohen, MD, Alfred L. Garfall, MD, Lifeng Tian, PhD, Simon F Lacey, PhD, Joseph A Fraietta, PhD, Jennifer Brogdon, PhD, Megan Davis, PhD, Vanessa E. Gonzalez, Bruce L Levine, PhD, Don L. Siegel, MD PhD, Michael C. Milone, Edward A. Stadtmauer, MD FACP, Carl H June, MD, J. Joseph Melenhorst, PhD

Blood (2019) 134 (Supplement_1): 1909.

https://doi.org/10.1182/blood-2019-122396

Published: 2019

Journal Articles

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Blood (2019) 134 (Supplement_1): 49.

https://doi.org/10.1182/blood-2019-122374

Published: 2019

Journal Articles

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy

Jaco A. C. van Bruggen, Anne W. J. Martens, Joseph A. Fraietta, Tom Hofland, Sanne H. Tonino, Eric Eldering, Mark-David Levin, Peter J. Siska, Sanne Endstra, Jeffrey C. Rathmell, Carl H. June, David L. Porter, J. Joseph Melenhorst, Arnon P. Kater, Gerritje J. W. van der Windt

Blood (2019) 134 (1): 44–58.

https://doi.org/10.1182/blood.2018885863

Published: 2019

Includes: Supplemental data

Journal Articles

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8 + T Cells and Impede CAR T Cell Efficacy

Jaco A. C. Van Bruggen, MSc, Anne W. J. Martens, MSc, Joseph A Fraietta, PhD, Tom Hofland, MSc, Sanne Tonino, MD PhD, Eric Eldering, PhD, Mark-David Levin, MDPhD, Peter J. Siska, MD, Sanne Endstra, Jeffrey C Rathmell, PhD, Carl H June, MD, David L. Porter, MD, J. Joseph Melenhorst, PhD, Gerritje J. W. van der Windt, PhD, Arnon P. Kater, MD

Blood (2018) 132 (Supplement 1): 235.

https://doi.org/10.1182/blood-2018-99-115911

Published: 2018

Journal Articles

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

J. Joseph Melenhorst, PhD, David L. Porter, MD, Lifeng Tian, PhD, Simon F Lacey, PhD BS, Christopher L Nobles, PhD, Joseph A Fraietta, PhD, Noelle V. Frey, MD, Irina Kulikovskaya, Minnal Gupta, Regina M Young, PhD, David E Ambrose, BS, Don L. Siegel, MD PhD, Frederic D Bushman, PhD, Carl H June, MD

Blood (2018) 132 (Supplement 1): 699.

https://doi.org/10.1182/blood-2018-99-117390

Published: 2018

Journal Articles

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Christopher L Nobles, PhD, John K Everett, Shantan Reddy, Joseph A Fraietta, PhD, David L. Porter, MD, Noelle V. Frey, MD, Stephan A. Grupp, MD PhD, Don L. Siegel, MD PhD, Simon F Lacey, PhD BS, Carl H June, MD, Frederic D Bushman, PhD, J. Joseph Melenhorst, PhD

Blood (2018) 132 (Supplement 1): 4548.

https://doi.org/10.1182/blood-2018-99-117034

Published: 2018

NARROW

Curing CLL: Long-Term Outcomes of Chronic Lymphocytic Leukemia Patients with at Least One Year of Response to CART-19 Therapy

Deciphering the Impact of Immunological Aging in CLL CAR T Cell Therapy

Efficacy and Safety of Anti-CD19 and Anti-BCMA Chimeric Antigen Receptor (CAR) T-Cell Therapies in Patients with Autoimmune Disease and Lymphoma or Myeloma

In Vivo Persistence and Function of CAR19 T-Cell Products for Pediatric B-Cell Acute Lymphoblastic Leukemia Are Impacted By Media, Cytokine Supplementation and Metabolite Bioavailability during Ex Vivo Manufacturing

Cost-Effective Manufacture and Promising Initial Efficacy of huCART19 Cells Manufactured Using the Clinimacs Prodigy Platform

Selective Support of CAR-T Cell Therapies By Cis-Targeted IL-2 Enhances Anti-Tumor Activity and Obviates the Need for Lymphodepletion in Non-Human Primates

BTK Inhibition Prevents the Induction of Myeloid-Derived Suppressor Cells in Malignancy and Improves CART Function

Bendamustine Is Less Toxic Than Fludarabine-Cyclophosphamide-Based Lymphodepletion before CD28-Costimulated CART19 through Reduced Inflammatory Cytokines

IL-10 Levels Differentially Regulate IFNg Signaling of CART19 and CART22

Cytokine Release Syndrome Results in Reduced AML Killing By CD123 CAR T Cells

CD22-Targeted CAR-Modified T-Cells Safely Induce Remissions in Children and Young Adults with Relapsed, CD19-Negative B-ALL after Treatment with CD19-Targeted CAR T-Cells

Decade-Long Remissions of Leukemia Sustained By the Persistence of Activated CD4+ CAR T-Cells

Hypogammaglobulinemia and Infection Risk in Chronic Lymphocytic Leukemia (CLL) Patients Treated with CD19-Directed Chimeric Antigen Receptor T (CAR-T) Cells

Identification and Validation of Predictive Biomarkers to CD19- and BCMA-Specific CAR T-Cell Responses in CAR T-Cell Precursors

Response to Anti-Bcma CAR T Cell Therapy Correlates with T Cell Exhaustion and Activation Status in T Cells at Baseline in Myeloma

First-in-Human Assessment of Feasibility and Safety of Multiplexed Genetic Engineering of Autologous T Cells Expressing NY-ESO -1 TCR and CRISPR/Cas9 Gene Edited to Eliminate Endogenous TCR and PD-1 (NYCE T cells) in Advanced Multiple Myeloma (MM) and Sarcoma

Chronic lymphocytic leukemia cells impair mitochondrial fitness in CD8 + T cells and impede CAR T-cell efficacy

Chronic Lymphocytic Leukemia Cells Impair Mitochondrial Fitness in CD8 + T Cells and Impede CAR T Cell Efficacy

Long-Term Remission of CLL Sustained By Pauciclonal Anti-CD19 Chimeric Antigen Receptor T (CTL019) Cell Clones

Vector Integration and Efficacy of CD19-Directed CAR T Cell Therapy in Acute Lymphoblastic Leukemia (ALL) and Chronic Lymphocytic Leukemia (CLL)

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only